Skip to main content
. 2001 Dec 1;108(11):1687–1695. doi: 10.1172/JCI13419

Figure 2.

Figure 2

Analysis of NLOs in CDG patients and a control subject. Metabolically labeled NLOs were isolated from a healthy individual (control subject) and from patients A, L, and S (CDG-If patient A, CDG-If patient L, CDG-If patient S). [3H]-labeled NLOs were cleaved from protein by incubation with PNGaseF, protein was removed by precipitation, and the liberated oligosaccharides were analyzed by HPLC using a radiodetector to monitor elution positions. Elution positions for standard oligosaccharide intermediates Man3GlcNAc2 to Glc1Man9GlcNAc2 (M3, M4, M5, M6, M7, M8, M9, G1M9) are given at the top of the figure.